Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Lymphoma, Non-Hodgkin 15Leukemia, Lymphocytic, Chronic, B-Cell 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Lymphoma, Follicular 12Recurrence 10Lymphoma, Mantle-Cell 9Lymphoma, Large B-Cell, Diffuse 9Lymphoma 9Lymphoma, B-Cell, Marginal Zone 8Leukemia 7Lymphoma, B-Cell 6Neoplasms 4Leukemia, Myeloid, Acute 4Burkitt Lymphoma 4Melanoma 3Lymphoma, Large-Cell, Anaplastic 3Hematologic Neoplasms 3Carcinoma, Renal Cell 3Waldenstrom Macroglobulinemia 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neuroblastoma 2Mastocytosis, Systemic 2Lymphoproliferative Disorders 2Lung Neoplasms 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Mast-Cell 2Leukemia, Biphenotypic, Acute 2Hodgkin Disease 2Hematologic Diseases 2

Interventions

blinatumomab 2pegaspargase 1asparaginase erwinia chrysanthemi recombinant 1Methotrexate 1Ifosfamide 1Dexamethasone 1Daunorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × Lymphoproliferative Disorders × Lymphoid × Clear all
NCT02393859 2024-05-29

Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)

Amgen

Phase 3 Completed
111 enrolled 23 charts 1 FDA
LymphoidOther hematologic neoplasm

Immunoproliferative Disorders, Lymphoproliferative Disorders, Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01207388 2020-02-10

BLAST

Amgen Research (Munich) GmbH

Phase 2 Completed
116 enrolled 23 charts 1 FDA
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡